IP Library › Granted Patent US 10,632,172
Granted Patent B2
US 10,632,172 · App. 16/438,872 · Granted Apr 28, 2020

Injectable self-assembling antibacterial peptide hydrogels

Inventors: Vivek A. Kumar (Newark, NJ); Peter Nguyen (New Rochelle, NY); Biplab Sarkar (Newark, NJ); Shivani Jaisinghani (Morganville, NJ)
Assignee: New Jersey Institute of Technology
A61K38/164A61K9/0014A61K9/0019A61K9/70A61L27/22A61L27/52A61L31/145A61L2400/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,632,172
App. No.
16/438,872
Granted
Apr 28, 2020
Kind
B2
Abstract

A set of cationic amphiphilic self-assembled peptides (CASPs) is presented that employ high-charge density at fiber edges to disrupt bacterial membranes. CASP nanofibers are effective against Pseudomonas biofilms. There is an inherent trade-off between the ability of the peptides to undergo nanofibrous self-assembly and having a high terminal charge density required for effective bactericidal efficacy. The self-assembled peptide hydrogel presented achieves a balance of these opposing factors. Also demonstrated is the applicability of the new composition in an injectable hydrogel formulation. A CASP platform may be useful for topical application and integration into medical coatings, grafts, devices, and prostheses, thereby reducing risk of bacterial infection and related failure.

Claims (25)

1. An anti-bacterial hydrogel, comprising

a cationic amphiphilic self-assembled peptide (CASP-K6) comprising SEQ. ID. NO. 3, and

wherein, the CASP-K6 is a hydrogel with a self-assembled nanofiber platform for disrupting bacterial colonies in stationary biofilms.

2. The anti-bacterial hydrogel of claim 1 , wherein the CASP-K6 intrinsically undergoes self-hydrogelation in aqueous solutions without addition of an exogenous gel base.

3. The anti-bacterial hydrogel of claim 2 , wherein the hydrogel is topically applied or integrated into a wound bed directly, or integrated into medical coatings, grafts, devices, and prostheses for reducing risk of bacterial infection and related failure.

4. The anti-bacterial hydrogel of claim 1 , wherein the peptide CASP-K6 inhibits growth of a bacterial biofilm.

5. The anti-bacterial hydrogel of claim 4 , wherein the bacterial biofilm further includes a colony of gram-negative bacteria.

6. The anti-bacterial hydrogel of claim 1 , wherein the peptide CASP-K6 forms an antibacterial hydrogel at a physiological pH and a physiological ionic strength without addition of a gel base including hypromellose to obtain a viscoelastic hydrogel formulation.

7. The anti-bacterial hydrogel of claim 1 , wherein a concentration of the CASP-K6 in aqueous solution resulting in aggregation or hydrogelation is 0.01 mg/ml-100 mg/ml.

8. A method of applying an antibacterial hydrogel, comprising:

providing an effective amount of a set of cationic amphiphilic self-assembled peptides (CASP-K6) that employ high-charge density to disrupt bacterial membranes comprising SEQ. ID. NO. 3;

wherein, the CASP-K6 is a hydrogel with a self-assembled nanofiber platform for disrupting bacterial colonies in stationary biofilms; and

delivering an injectable dosage of the peptide CASP-K6.

9. The method of claim 8 , wherein the delivering is through an injectable syringe, a topical application, or integration into a medical coating.

10. The method of claim 9 , wherein the medical coating is on a graft, a medical device, or prosthesis for reducing risk of a bacterial infection and a related failure.

11. The method of claim 8 , wherein the peptide CASP-K6 is injectable, persists in vivo, and sustains a localized efficacy for a prolonged period.

12. The method of claim 8 , further includes treating a localized infection to prevent bacterial growth or infection.

13. The method of claim 8 , further includes using the peptide CASP-K6 in conjugation with another biomaterial.

14. An anti-bacterial hydrogel, comprising

a cationic amphiphilic self-assembled peptide (CASP-K6) comprising SEQ. ID. NO. 3;

wherein, the CASP-K6 is a hydrogel with a self-assembled nanofiber platform for disrupting bacterial colonies in stationary biofilms; and

wherein a hydrogelation of the peptide CASP-K6 occurs in vivo under a physiological pH without addition of a gel base to form the hydrogel and wherein the gel has a storage modulus of greater than 100 Pascals (Pa).

15. The anti-bacterial hydrogel of claim 14 , wherein the hydrogelation is used for a topical application on an infected wound for rapid hemostasis and wound healing.

16. The anti-bacterial hydrogel of claim 5 , wherein the colony of gram-negative bacteria is Pseudomonas aeruginosa PAO1.

17. The anti-bacterial hydrogel of claim 6 , wherein the hydrogel has a storage modulus greater than 100 Pascals (Pa).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2019
From: KUMAR, VIVEK A.; NGUYEN, PETER; SARKAR, BIPLAB; JAISINGHANI, SHIVANI
To: NEW JERSEY INSTITUTE OF TECHNOLOGY
Reel/Frame 050916/0560 →
Continuity (2)
Provisional Application 62685616 · Jun 15, 2018
Related Publication 20200000875A1 · Jan 2, 2020
Cited By (1)
US 12,319,752